<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309478</url>
  </required_header>
  <id_info>
    <org_study_id>ABCSG-5</org_study_id>
    <nct_id>NCT00309478</nct_id>
  </id_info>
  <brief_title>Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients</brief_title>
  <official_title>A Randomized Phase III Study Comparing Cyclophosphamide + Methotrexate + Fluorouracil vs. Goserelin + Tamoxifen in Premenopausal, Hormone Receptor-positive, Lymph Node-positive or -Negative Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Austrian Breast &amp; Colorectal Cancer Study Group</source>
  <brief_summary>
    <textblock>
      Primarily, this clinical investigation compared the efficacy of cyclophosphamide +&#xD;
      methotrexate + fluorouracil chemotherapy vs. goserelin + tamoxifen treatment in terms of&#xD;
      prognosis (disease-free survival, overall survival) in premenopausal patients with&#xD;
      potentially curative, operated hormone receptor-positive breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1990</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1099</enrollment>
  <condition>Early-stage Breast Cancer</condition>
  <arm_group>
    <arm_group_label>2 (CMF scheme)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles CMF scheme (cyclophosphamide, methotrexate, fluorouracil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 (Nol + Zol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zoladex (3 years) combined with Nolvadex (5 years)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 600mg/m2</description>
    <arm_group_label>2 (CMF scheme)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate 40mg/m2</description>
    <arm_group_label>2 (CMF scheme)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil implant</intervention_name>
    <description>Fluorouracil 600mg/m2</description>
    <arm_group_label>2 (CMF scheme)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>Zoladex 3.6mg/28 days for 3 years</description>
    <arm_group_label>1 (Nol + Zol)</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Nolvadex 20mg/day for 5 years</description>
    <arm_group_label>1 (Nol + Zol)</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Premenopausal patients with histologically verified, lymph node-negative (pT1c-pT3) or&#xD;
             lymph node-positive (pT1a-pT3) breast cancer&#xD;
&#xD;
          -  Hormone receptor-positive status&#xD;
&#xD;
          -  More than 6 histologically examined lymph nodes&#xD;
&#xD;
          -  Laboratory parameters&#xD;
&#xD;
               1. hematopoiesis: &gt; 3500/µl leukocytes, &gt; 100,000/µl thrombocytes&#xD;
&#xD;
               2. renal function: creatinin &lt; 1.5mg %&#xD;
&#xD;
               3. hepatic function: GOT &lt;/= 2.5 x UNL&#xD;
&#xD;
               4. bilirubin: &lt; 1.5mg %&#xD;
&#xD;
               5. metabolic parameters: Na, Ca, K in normal range, normal level of blood sugar&#xD;
&#xD;
               6. blood coagulation: PZ &gt; 60%&#xD;
&#xD;
          -  Concluded healing process following surgery&#xD;
&#xD;
          -  &lt;/= 4 weeks interval since surgery&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T4 carcinoma; inflammatory breast cancer, carcinoma in situ&#xD;
&#xD;
          -  Simultaneous or sequential bilateral breast cancer&#xD;
&#xD;
          -  Preoperative tumor-reducing radiotherapy or preoperative tumor-specific medical&#xD;
             treatment&#xD;
&#xD;
          -  Male patients&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Lacking compliance or understanding of the disease&#xD;
&#xD;
          -  General contraindication against cytostatic treatment&#xD;
&#xD;
          -  Serious concomitant disease preventing implementation of adjuvant therapy or regular&#xD;
             follow-up&#xD;
&#xD;
          -  Second carcinoma or status post second carcinoma (except for curatively treated&#xD;
             squamous cell carcinoma of the skin or cervical carcinoma in situ)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raimund Jakesz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <link>
    <url>http://www.abcsg.at</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>Goserelin</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

